Reference: GILA/ID/REM-067/PHARMA
Board seat: Independent Director, Non-Executive
Primary board location: Mumbai with western India manufacturing sites
Meeting model: Six boards, monthly Quality/Remediation Committee and plant visits
Mandate type: Governance Remediation & Confidence Restoration
Status: Confidential live-search specification; client identity released only after conflict clearance and NDA.
The anonymised enterprise
A listed generic-drug manufacturer exporting oral solids and sterile products to regulated and semi-regulated markets.
Revenue is ₹5,000–7,000 crore. A foreign regulator issued material observations at one plant; no conclusion of misconduct is assumed, and an independent remediation programme is underway.
The board problem and strategic reason for appointment
The board requires a director who can govern fact-finding, patient risk, data integrity, production decisions and sustainable remediation without managing the quality function or prejudging regulatory outcome.
The board is not buying a credential. It is appointing an independent decision-maker who can convert this problem into a governed sequence of choices, evidence and accountability. Success will be judged by the quality of decisions and control improvement, not by the number of recommendations made.
Board position, authority and interfaces
Chair of Board Quality & Remediation Committee; Audit member for provisions, inventory and disclosure; direct access to Chief Quality Officer and external monitor.
The appointee will have direct, unfiltered access to the Company Secretary and to the relevant control-function leaders. Any advisory support requested by the board must remain management-executed: the director sets questions, tolerances and evidence standards, but does not become an executive or consultant.
First 12–18 month strategic charter
- Approve investigation scope, independence, privilege and evidence preservation; set product/batch risk and market-action decision protocol; track CAPA effectiveness, data-integrity and quality-culture root causes; align regulator, customer, auditor and investor disclosures to verified facts
- Own a fact-led remediation architecture: allegation intake, independence of investigation, privilege protocol, evidence preservation, root cause, individual accountability and tracked closure.
- Rebuild confidence through verifiable changes to controls, incentives, information flow and board behaviour; communications must follow evidence and must never pre-judge guilt or innocence.
Decision profile sought
Essential evidence
- Global pharma quality, regulator, remediation, audit or manufacturing leader; board independence; inspection-response and patient-risk judgement
Differentiators
- Consent-decree/import-alert recovery, data-integrity investigation or external monitor experience; ability to challenge production pressure
GILA will assess independence under reputational pressure, investigations or control-remediation experience, procedural fairness and willingness to insist on evidence even when every stakeholder wants speed. Candidates should expect a case discussion based on an ambiguous board decision from this mandate, not a career-history interview alone.
Independence, suitability and downside diligence
The search will apply Section 149(6), Sections 164–165, Schedule IV and the applicable listing or sector rules to the entity’s legally verified status at the appointment date. Databank/proficiency status, listed-entity directorship and committee ceilings, pecuniary relationships, relatives’ interests, recent audit/advisory work and interlocking directorships will be checked. The appointment is subject to formal legal and secretarial confirmation; this posting is not a substitute for that determination.
Mandate-specific screens: Prior plant audit/consulting, competitor, customer or regulator conflicts; involvement in the event; commercial interest in remediation vendors.
Before accepting the seat, the candidate will receive under NDA the latest board composition, committee charters, material litigation/regulatory schedule, related-party map, last audited accounts, current D&O policy and the specific risk papers necessary to make an informed liability assessment.
Twelve-month outcomes
The board expects closed root causes, restored control credibility and stakeholder communication that can withstand regulatory, audit and judicial scrutiny. For this particular seat, the evidence will be:
- Root causes and affected scope independently established; CAPA effectiveness verified beyond document closure; disclosures remain accurate and non-prejudicial
Commitment, protection and economics
- Expected load: 32–40 days in remediation year.
- Terms: Five-year term; committee-chair fee; regulatory investigation, product and D&O cover with independent counsel.
- Protection: Appointment letter, deed of indemnity where legally available, appropriate D&O cover including discovery/run-off terms, access to independent advice under the board-approved protocol, and complete minuting of dissent.
- Equity: No stock options where the appointment is legally an independent-director seat subject to Section 149(9). Any private-company structure outside that perimeter will be expressly classified and separately advised; no equity is implied by this posting.
Search process
Conflict pre-clearance → GILA/SYMPHONY™ board-fit interview → mandate case → document-led diligence under NDA → references from board peers and control functions → NRC/owner interviews → statutory, regulatory and reputation checks → board recommendation. Candidate consent, disclosures and appointment approvals will follow the law and the entity’s constitutional documents.